Gu D, Hu L, Huang S, Guo L
Cytojournal. 2025; 21:70.
PMID: 39917015
PMC: 11801688.
DOI: 10.25259/Cytojournal_59_2024.
Elshafey M, Ghandour M, Adams R, Neill D, Gogoi R
Gynecol Oncol Rep. 2025; 57:101653.
PMID: 39758708
PMC: 11699607.
DOI: 10.1016/j.gore.2024.101653.
Wei Y, Zhang R, Yin R, Wang S, Han J, Chen R
Clin Respir J. 2024; 18(9):e70000.
PMID: 39275901
PMC: 11399776.
DOI: 10.1111/crj.70000.
Xu X, Liu B, Su Y, Dong P, Wang S, Deng J
J Thorac Dis. 2024; 16(8):5152-5166.
PMID: 39268117
PMC: 11388250.
DOI: 10.21037/jtd-23-1927.
Shao M, Fan S, Qi W, Luo Z, Xu R, Liao F
Front Med (Lausanne). 2024; 11:1415042.
PMID: 39144665
PMC: 11323557.
DOI: 10.3389/fmed.2024.1415042.
Premalignant Progression in the Lung: Knowledge Gaps and Novel Opportunities for Interception of Non-Small Cell Lung Cancer. An Official American Thoracic Society Research Statement.
Moghaddam S, Savai R, Salehi-Rad R, Sengupta S, Kammer M, Massion P
Am J Respir Crit Care Med. 2024; 210(5):548-571.
PMID: 39115548
PMC: 11389570.
DOI: 10.1164/rccm.202406-1168ST.
Complete Favorable Response after Second-Line Immunotherapy in Stage IV Non-Small Lung Cancer with Visceral Metastases and Operated Brain Metastasis.
Rahnea-Nita R, Rebegea L, Toma R, Nechifor A, Constantin G, Rahnea-Nita G
J Pers Med. 2024; 14(7).
PMID: 39064008
PMC: 11278410.
DOI: 10.3390/jpm14070754.
Evolution and genotypic characteristics of small cell lung cancer transformation in non-small cell lung carcinomas.
Zhong J, Li X, Wang Z, Duan J, Li W, Zhuo M
J Natl Cancer Cent. 2024; 1(4):153-162.
PMID: 39036802
PMC: 11256618.
DOI: 10.1016/j.jncc.2021.11.001.
[NUT cancer of nasal cavity and sinuses: a case report and literature review].
Wang Y, Zhao J, Zhou X, Liu J
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2024; 38(6):530-533.
PMID: 38858120
PMC: 11480580.
DOI: 10.13201/j.issn.2096-7993.2024.06.014.
Surgery challenges and postoperative complications of lung cancer after neoadjuvant immunotherapy.
Bai G, Chen X, Peng Y, Ji Y, Bie F, Liu Y
Thorac Cancer. 2024; 15(14):1138-1148.
PMID: 38572774
PMC: 11091790.
DOI: 10.1111/1759-7714.15297.
Fusing Diverse Decision Rules in 3D-Radiomics for Assisting Diagnosis of Lung Adenocarcinoma.
Ren H, Wang Q, Xiao Z, Mo R, Guo J, Hide G
J Imaging Inform Med. 2024; 37(5):2135-2148.
PMID: 38565729
PMC: 11522261.
DOI: 10.1007/s10278-024-00967-5.
Downregulation of microRNA‑494 inhibits cell proliferation in lung squamous cell carcinoma via the induction of PUMA‑α‑mediated apoptosis.
Gao X, Yang X, He F, Liu X, Liu D, Yuan X
Exp Ther Med. 2023; 25(6):242.
PMID: 37153893
PMC: 10160919.
DOI: 10.3892/etm.2023.11941.
A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells.
Ghaderi A, Okhovat M, Lehto J, De Petris L, Doulabi E, Kokhaei P
Pharmaceutics. 2023; 15(4).
PMID: 37111634
PMC: 10145660.
DOI: 10.3390/pharmaceutics15041148.
Bilateral infiltrative kidney metastasis due to non-keratinizing squamous cell carcinoma of the lung: lesson for the clinical nephrologist.
Stefan G, Chiriac C, Stancu S, Zugravu A, Petre N
J Nephrol. 2023; 36(6):1703-1706.
PMID: 37036662
DOI: 10.1007/s40620-023-01627-7.
CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma.
He J, Lan X, Liu X, Deng C, Luo H, Wang Y
BMC Cancer. 2023; 23(1):266.
PMID: 36959566
PMC: 10035219.
DOI: 10.1186/s12885-023-10735-3.
Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer.
Wang M, Zhu L, Yang X, Li J, Liu Y, Tang Y
Front Pharmacol. 2023; 14:1132158.
PMID: 36874015
PMC: 9974851.
DOI: 10.3389/fphar.2023.1132158.
Indeterminate pulmonary subsolid nodules in patients with no history of cancer: growing prediction, CT pattern, and pathological diagnosis.
Guo X, Jia X, Zhang D, Feng H, Dou Y, Shi G
Diagn Interv Radiol. 2022; 28(3):230-238.
PMID: 35748205
PMC: 9634916.
DOI: 10.5152/dir.2022.211100.
Epidemiology and survival outcomes in adenosquamous carcinoma: a population-based study.
Cheng C, Luo Z, Xiong W, Shi Z, Tan H
Int J Colorectal Dis. 2022; 37(7):1581-1592.
PMID: 35678851
DOI: 10.1007/s00384-022-04198-4.
Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer.
Huang L, Liao Z, Liu Z, Chen Y, Huang T, Xiao H
Front Pharmacol. 2022; 13:900825.
PMID: 35620280
PMC: 9127258.
DOI: 10.3389/fphar.2022.900825.
Advances in the pathogenesis and treatment of nut carcinoma: a narrative review.
Wang S, Li J, Tong W, Li H, Feng Q, Teng B
Transl Cancer Res. 2022; 9(10):6505-6515.
PMID: 35117258
PMC: 8798738.
DOI: 10.21037/tcr-20-1884.